Per Artikel

Riset dan Pengabdian Masyarakat Do Research Sosial Service and Innovation

Id	Authors	Author S Id	Title	Year	Source Title	Volume	Issue	Page Start	Page End	Cited By	Link	Affiliations	Authors With Affiliations	Abstract	Author Keywords	Index Keywords	Publisher	Issn	Pubmed Id	Document Type	Sjr Best Quartile	Sjr	Sjr Rank
Display # Page 82 of 93 Start Prev 77 78 79 80 81 82 83 84 85 86 Next End
629(1)
No records
240	Nathania M., Sunardi D.	57245860300;57192075078;	The importance of balanced nutrition to fortify the immune system during the covid-19 outbreak [La importancia de una nutrición equilibrada para aumentar el sistema inmunológico durante el brote de covid-19]	2021	Revista Chilena de Nutricion	48	4	620	629		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114246311&doi=10.4067%2fS0717-75182021000400620&partnerID=40&md5=c999acae5c75b659b516d0fbb8b1815b	Department of Nutrition, Faculty of Medicine, University of Indonesia-Ciptomangunkusumo National Hospital, Jakarta Pusat, 10430, Indonesia	Nathania, M., Department of Nutrition, Faculty of Medicine, University of Indonesia-Ciptomangunkusumo National Hospital, Jakarta Pusat, 10430, Indonesia; Sunardi, D., Department of Nutrition, Faculty of Medicine, University of Indonesia-Ciptomangunkusumo National Hospital, Jakarta Pusat, 10430, Indonesia	COVID-19, first reported in December 2019 in Wuhan, China, quickly spread worldwide and was announced as a pandemic in March 2020. As symptoms and outcomes are varied, the elderly and those who have at least one comorbidity (diabetes, cardiovascular disorders or other chronic diseases) are considered to be at high risk and are generally have lower immunity. An optimal immune system is critical for survival, as it protects the body against infectious agents. Nutrition is an essential factor in the immune system, contributing to components in physical barriers, biochemical, innate and adaptive immunity. Research advances show that nutritional deficiencies, namely the inadequacy of energy, macronutrients and micronutrients, affect the immune system and increase infection risk. The following discussion explains the comprehensive role of nutrition in the immune system, nutrition recommendations that can be used as precautions and the need for supplementation during this outbreak. © 2021, Sociedad Chilena de Nutricion Bromatologia y Toxilogica. All rights reserved.	COVID-19; Immune; Nutrition; Pandemic; Supplementation		Sociedad Chilena de Nutricion Bromatologia y Toxilogica	07177518		Review	Q4	182	20570	View
632(1)
No records
579	Lee C.-C., Kwa A.L.H., Apisarnthanarak A., Feng J.-Y., Gluck E.H., Ito A., Karuniawati A., Periyasamy P., Pratumvinit B., Sharma J., Solante R., Swaminathan S., Tyagi N., Vu D.M., Zirpe K., Schuetz P.	57216571107;57277379200;6603905554;24168534700;7003341685;37007598100;54886816200;57218573063;35722893000;12545686500;8728553100;56354453600;56471440500;57214066572;56521747700;35235208800;	Erratum: Procalcitonin (PCT)guided antibiotic stewardship in Asia-Pacific countries: Adaptation based on an expert consensus meeting. (Clin Chem Lab Med (2020) 58:12 (1983–91) Doi:10.1515/cclm-2019-1122)	2021	Clinical Chemistry and Laboratory Medicine	59	3	631	632		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100458517&doi=10.1515%2fcclm-2020-1724&partnerID=40&md5=b517d7656483da02741274bbd916bf57	Singapore General Hospital, Singapore, Singapore; Emerging Infectious Diseases Program, Duke-National University of Singapore Medical School, Singapore, Singapore; Division of Infectious Diseases, Thammasart University Hospital, Bangkok, Thailand; Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Critical Care Services, Swedish Covenant Hospital, Chicago, IL, United States; Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, Okayama, Japan; Department of Microbiology, Faculty of Medicine, Universitas Indonesia and Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Infectious Disease Unit, PPUKM (HCTM), Hospital Canselor Tuanku Muhriz UKM (HCTM), Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, Malaysia; Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Artemis Hospital Critical Care Medicine, Gurgaon, India; Adult Infectious Diseases and Tropical Medicine, San Lazaro Hospital, Manila, Philippines; Infectious Diseases, Gleneagles Global Hospitals, Chennai and Bengaluru, India; Institute of Critical Care and Emergency Medicine, Sir Ganga Ram Hospital, Delhi, India; Critical Care Department, National Hospital of Tropical Diseases, Hanoi, Viet Nam; Department of Neuro Critical Care, Ruby Hall Clinic, Grant Medical Foundation, Pune, India; Department of Internal Medicine, Kantonsspital Aarau, Aarau, Switzerland; University of Basel, Basel, Switzerland	Lee, C.-C., Singapore General Hospital, Singapore, Singapore; Kwa, A.L.H., Emerging Infectious Diseases Program, Duke-National University of Singapore Medical School, Singapore, Singapore, Division of Infectious Diseases, Thammasart University Hospital, Bangkok, Thailand; Apisarnthanarak, A., Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Feng, J.-Y., Critical Care Services, Swedish Covenant Hospital, Chicago, IL, United States; Gluck, E.H., Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, Okayama, Japan; Ito, A., Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, Okayama, Japan; Karuniawati, A., Department of Microbiology, Faculty of Medicine, Universitas Indonesia and Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Periyasamy, P., Infectious Disease Unit, PPUKM (HCTM), Hospital Canselor Tuanku Muhriz UKM (HCTM), Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, Malaysia; Pratumvinit, B., Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Sharma, J., Artemis Hospital Critical Care Medicine, Gurgaon, India; Solante, R., Adult Infectious Diseases and Tropical Medicine, San Lazaro Hospital, Manila, Philippines; Swaminathan, S., Infectious Diseases, Gleneagles Global Hospitals, Chennai and Bengaluru, India; Tyagi, N., Institute of Critical Care and Emergency Medicine, Sir Ganga Ram Hospital, Delhi, India; Vu, D.M., Critical Care Department, National Hospital of Tropical Diseases, Hanoi, Viet Nam; Zirpe, K., Department of Neuro Critical Care, Ruby Hall Clinic, Grant Medical Foundation, Pune, India; Schuetz, P., Department of Internal Medicine, Kantonsspital Aarau, Aarau, Switzerland, University of Basel, Basel, Switzerland	There is typo in Figure 1 and Figure 2 of this article. Instead of “… repeated testing or monitoring for discontinuation …” it should read “… repeated testing for monitoring and discontinuation …” (see corrected Figures). © 2021 De Gruyter. All rights reserved.		erratum	De Gruyter Open Ltd	14346621	33554531	Erratum	Q1	977	4522	View
633(1)
No records
744	Rinaldi I., Sari R.M., Tedhy V.U., Winston K.	23475122400;57208474079;57226362042;57224165400;	Leukapheresis does not improve early survival outcome of acute myeloid leukemia with leukostasis patients – A dual-center retrospective cohort study	2021	Journal of Blood Medicine	12		623	633	1	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111261844&doi=10.2147%2fJBM.S312140&partnerID=40&md5=ef2e5f0e39b0ea908c07e71bba0bf1a4	Division of Hematology and Medical Oncology, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia	Rinaldi, I., Division of Hematology and Medical Oncology, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sari, R.M., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Tedhy, V.U., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Winston, K., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia	Introduction: Leukostasis is a medical emergency with high mortality which often occurs in acute myeloid leukemia patients with hyperleukocytosis. One of the therapies that can be used for leukostasis in acute myeloid leukemia is leukapheresis. However, whether leukapheresis can provide better survival benefit when compared with patients not receiving leukapheresis is still unclear. Hence, we aimed to evaluate the effect of chemotherapy plus leukapheresis combination versus chemotherapy only on 28-day survival of acute myeloid leukemia patients with leukostasis. Methods: This study was a dual-center retrospective cohort using secondary data from medical records collected from November 2018 to March 2019. Inclusion criteria were adult patients aged 18 years old or above, diagnosed with acute leukemia with hyperleukocytosis status defined by WBC count greater than 100,000/uL, and with symptoms of leukostasis. One-month survival analysis was conducted using Kaplan–Meier curve method. Univariate and multivariate analyses were then conducted using Cox proportional hazards model to obtain value of hazard ratio (HR) with a 95% confidence interval (CI). Results: A total of 38 patients were obtained for analysis. The median overall survival was 25 days (95% CI: 17.001–32.999 days) in the chemotherapy only group and 20 days (95% CI: 1.497–38.503) in the chemotherapy with leukapheresis group. The use of leukapheresis did not affect 28-day survival (HR: 1.140; 95% CI: 0.396–3.283; p value: 0.809) and 7-day survival (HR: 1.073; 95% CI: 0.277–4.152; p value: 0.919). In the multivariate analysis, age ≥60 years, blast percentage ≥90%, creatinine ≥1.4 mg/dL, and presence of disseminated intravascular coagulation were associated with worse 28-day survival. Conclusion: AML patients with leukostasis who received both chemotherapy and leuka-pheresis did not have better 28-day survival and 7-day survival when compared with patients receiving chemotherapy only. Old age, high blast percentage, high creatinine, and presence of disseminated intravascular coagulation were prognostic factors for worse 28-day survival. © 2021 Rinaldi et al.	Chemotherapy; Hyperleukocytosis; Leukapheresis; Leukemia; Leukostasis; Survival	creatinine; gluconate calcium; hemoglobin; lactate dehydrogenase; vascular cell adhesion molecule 1; acute myeloid leukemia; adult; allogeneic hematopoietic stem cell transplantation; Article; blood transfusion; cancer prognosis; chronic myeloid leukemia; clinical article; cohort analysis; de novo acute myeloid leukemia; dyspnea; female; heart failure; human; hypertension; hypocalcemia; Kaplan Meier method; leukapheresis; leukocyte count; leukocytosis; leukostasis; lymphocyte count; male; mean corpuscular hemoglobin; mean corpuscular volume; mean platelet volume; observational study; overall survival; platelet count; platelet lymphocyte ratio; pneumothorax; red blood cell distribution width; retrospective study; risk factor; thrombocyte aggregation	Dove Medical Press Ltd	11792736		Article	Q3	676	7401	View
643(2)
No records
138	Gunardi T.H., Susantono D.P., Victor A.A., Sitompul R.	57195939686;57353411000;57191055282;8312163900;	Atopobiosis and dysbiosis in ocular diseases: Is fecal microbiota transplant and probiotics a promising solution?	2021	Journal of Ophthalmic and Vision Research	16	4	631	643		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119915775&doi=10.18502%2fJOVR.V16I4.9754&partnerID=40&md5=8d0e2b295a398c85ff1c28564276103b	Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Ophthalmology, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia	Gunardi, T.H., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Susantono, D.P., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Victor, A.A., Department of Ophthalmology, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sitompul, R., Department of Ophthalmology, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia	Purpose: To highlight the role of atopobiosis and dysbiosis in the pathomechanism of autoimmune uveitis, therefore supporting fecal microbiota transplant (FMT) and probiotics as potential targeted-treatment for uveitis. Methods: This review synthesized literatures upon the relation between gut microbiota, autoimmune uveitis, FMT, and probiotics, published from January 2001 to March 2021 and indexed in PubMed, Google Scholar, CrossRef. Results: The basis of the gut-eye axis revolves around occurrences of molecular mimicry, increase in pro-inflammatory cytokines, gut epithelial barrier disruption, and translocation of microbes to distant sites. In patients with autoimmune uveitis, an increase of gut Fusobacterium and Enterobacterium were found. With current knowledge of aforementioned mechanisms, studies modifying the gut microbiome and restoring the physiologic gut barrier has been the main focus for pathomechanism-based therapy. In mice models, FMT and probiotics targeting repopulation of gut microbiota has shown significant improvement in clinical manifestations of uveitis. Consequently, a better understanding in the homeostasis of gut microbiome along with their role in the gut-eye axis is needed to develop practical targeted treatment. Conclusion: Current preliminary studies are promising in establishing a causative gut-eye axis relationship and the possibility of conducting FMT and probiotics as targeted treatment to mitigate autoimmune uveitis, to shorten disease duration, and to prevent further complications. © 2021 GUNARDI ET AL. THIS IS AN OPEN ACCESS ARTICLE DISTRIBUTED UNDER THE CREATIVE COMMONS ATTRIBUTION LICENSE \| PUBLISHED BY KNOWLEDGE E	Atopobiosis; Autoimmune; Dysbiosis; Gut-Eye Axis; Uveitis		Knowledge E	20082010		Review	Q3	557	9058	View
168	Andriyati R., Firman D., Kurniawati Y., Alkatiri A.A., Pranata R., Muliawan H.S., Rossimarina V., Soerianata S.	57219712507;54898724100;57199153189;57210302708;57201973901;57203644653;57219708502;6504387197;	Improved clinical outcome with biodegradable polymer drug-eluting stents compared to durable polymer drug-eluting stents for primary percutaneous coronary intervention	2021	Postgraduate Medical Journal	97	1152	638	643		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094912557&doi=10.1136%2fpostgradmedj-2020-138243&partnerID=40&md5=10b39bd26552fd6e6283165f7c0afe78	Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia	Andriyati, R., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Firman, D., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Kurniawati, Y., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Alkatiri, A.A., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Pranata, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Muliawan, H.S., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Rossimarina, V., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Soerianata, S., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia	Background Studies comparing the clinical outcomes of second-generation biodegradable polymer drug-eluting stents (BP-DES) and second-generation durable polymer drug-eluting stents (DP-DES) in patients with ST-segment elevation myocardial infarction (STEMI) with follow-up duration of more than 1 year are still limited. Objective This study aimed to compare the 2-year clinical outcome of BP-DES with second-generation DP-DES in patients undergoing primary percutaneous coronary intervention (PPCI). Methods This is a retrospective cohort study in patients with STEMI, the primary endpoint was major adverse cardiac events (MACE) defined as recurrent myocardial infarction, total repeat revascularisation and cardiac death. The secondary endpoint was stent thrombosis (ST) defined as definite, probable or possible. Results A total of 400 patients were analysed (197 BP-DES groups and 203 DP-DES groups). BP-DES were independently associated with lower incidence of MACE (adjusted HR 0.67, 95% CI 0.21 to 0.91, p=0.005) and ST (adjusted HR 0.62, 95% CI 0.19 to 0.73, p<0.016) within 2 years of follow-up. Subgroup analysis of MACE individual components showed that BP-DES were associated with lower cardiac deaths (HR 0.35; 95% CI 0.18 to 0.94; p<0.001) compared to DP-DES, but not recurrent myocardial infarction and total repeat revascularisation. Conclusions BP-DES were associated with better clinical outcomes compared to second-generation DP-DES in patients with STEMI undergoing PPCI. ©	adult cardiology; Cardiology; coronary heart disease; coronary intervention; ischaemic heart disease; myocardial infarction	acetylsalicylic acid; beta adrenergic receptor blocking agent; clopidogrel; creatinine; glucose; hydroxymethylglutaryl coenzyme A reductase inhibitor; ticagrelor; troponin I; troponin T; polymer; acute heart infarction; adult; Article; chronic kidney failure; clinical outcome; cohort analysis; controlled clinical trial; controlled study; coronary angiography; diabetes mellitus; diastolic blood pressure; dual antiplatelet therapy; dyslipidemia; female; fibrinolytic therapy; heart death; heart infarction; heart left ventricle ejection fraction; heart rate; human; hypertension; incidence; major adverse cardiac event; major clinical study; male; middle aged; mortality; non ST segment elevation myocardial infarction; observational study; percutaneous coronary intervention; retrospective study;	BMJ Publishing Group	00325473	32796116	Article	Q2	568	8912	View
644(1)
No records
300	Muharam R., Rizal M.S.	57191492732;57226812403;	Correlation of calprotectin serum levels with degrees of endometriosis: A cross-sectional study	2021	International Journal of Reproductive BioMedicine	19	7	637	644		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112743809&doi=10.18502%2fijrm.v19i7.9474&partnerID=40&md5=34cae0bd86e4721b17270090a5a30ef4	Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia	Muharam, R., Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Rizal, M.S., Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia	Background: Endometriosis is closely associated with delayed diagnosis due to the lack of a definitive and sensitive noninvasive approach. The use of calprotectin in inflammatory process has been demonstrated in various inflammatory diseases. Calprotectin has a significant correlation with high-sensitivity C-reactive protein (hs-CRP) and could be used as an inflammatory marker. No study thus far has evaluated the correlation between calprotectin and endometriosis. Objective: To determine the correlation of calprotectin with the degree of endometriosis in order to help clinicians in establishing better early detection and management. Materials and Methods: In this cross-sectional study, 46 women referred to the Cipto Mangunkusumo, Fatmawati, and Persahabatan Hospitals in Jakarta, Indonesia between July 2017 and April 2018 were enrolled, and their blood serum were taken a day before surgery. Calprotectin serum level was treated using the Phical® ELISA method. After the diagnosis of endometriosis was confirmed through pathological examination, the final diagnosis of endometriosis could be established. The degree of endometriosis was classified according to the revised American Society for Reproductive Medicine (ASRM) classification. Results: The prevalence of minimal, mild, moderate, and severe degrees of endometriosis were 15.2, 39.1, 34.8, and 10.9%, respectively. The median serum calprotectin levels for minimal, mild, moderate, and severe endometriosis were 138.98, 121.49, 124.16, and 122.82 mg/mL, respectively. No correlation was observed between calprotectin and the degrees of endometriosis (r = –0.16, p = 0.278). Conclusion: There is no correlation between calprotectin serum levels and the degrees of endometriosis. © Muharam et al.	C-reactive protein; Calprotectin; Endometriosis; Inflammation	biological marker; C reactive protein; calgranulin; adolescent; adult; Article; body mass; correlation coefficient; cross-sectional study; diabetes mellitus; diastolic blood pressure; early diagnosis; endometriosis; enzyme linked immunosorbent assay; female; female infertility; glucose blood level; human; hypertension; major clinical study; protein expression	Research and Clinical Center for Infertitlity	24764108		Article	Q3	445	11118	View
6462(1)
No records
665	Atmakusuma T.D., Nasution I.R., Sutandyo N.	57216961785;8259214700;26028099200;	Oxidative stress (Malondialdehyde) in adults beta-thalassemia major and intermedia: Comparison between before and after blood transfusion and its correlation with iron overload	2021	International Journal of General Medicine	14		6455	6462		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119614825&doi=10.2147%2fIJGM.S336805&partnerID=40&md5=31da8ca15b655debd14557088a36df4a	Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Division of Hematology-Medical Oncology, Department of Internal Medicine, Gatot Soebroto Army Hospital Jakarta/Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Hematology-Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital Jakarta/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia	Atmakusuma, T.D., Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Nasution, I.R., Division of Hematology-Medical Oncology, Department of Internal Medicine, Gatot Soebroto Army Hospital Jakarta/Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sutandyo, N., Division of Hematology-Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital Jakarta/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia	Background: Iron overload is a major problem in both transfusion-dependent (TDT) and non-transfusion-dependent thalassemia (NTDT). It has been known to increase oxidative stress. Meanwhile, blood transfusion as main therapy for thalassemia increases iron overload. One of the markers of oxidative stress is malondialdehyde (MDA). This study aims to provide data on MDA levels in adult thalassemia patients, and to compare the levels before and after transfusion in patients with TDT and NTDT. Methods: This is a cross-sectional, pre-post study in adult patients with thalassemia major and intermedia that received blood transfusion with or without iron-chelating agents in Cipto Mangunkusumo Hospital. Blood samples were taken immediately before the transfusion and one day after. Serum ferritin (SF) assays were conducted by electrochemiluminescence immunoassay method, while transferrin saturation (TS) was calculated by dividing serum iron by the binding capacity. Subsequently, plasma MDA levels assays were performed using the Wills method, and data analysis was conducted using the t-test/Mann–Whitney and Pearson/Spearman correlation test, depending on the data distribution. Results: The 63 respondents recruited consist of 51 TDT and 12 NTDT patients, and their median plasma MDA level before and after transfusion was 0.49 µmol/L and 0.45 µmol/L, respectively. Before transfusion, there was no correlation between SF and MDA, and TS and MDA levels. After the transfusion, there was no correlation between, SF and MDA, or TS and MDA levels. Conclusion: There is no significant difference in MDA levels before and after transfusion. Although blood transfusion increases the iron load in thalassemia patients, there was no increase in median MDA level after transfusion. Meanwhile, there was no correlation between markers of iron overload and MDA level in thalassemia patients both before and after transfusion. © 2021 Atmakusuma et al. This work is published and licensed by Dove Medical Press Limited.	Iron overload; Malondialdehyde; Non-transfusion dependent thalassemia; Oxidative stress; Transfusion-dependent thalassemia	deferasirox; deferiprone; deferoxamine; ferritin; malonaldehyde; adult; aged; Article; blood transfusion; controlled study; cross-sectional study; female; ferritin blood level; hemoglobin E-beta thalassemia; human; Indonesia; iron chelation; iron overload; major clinical study; male; non transfusion dependent thalassemia; oxidative stress; thalassemia major; transferrin saturation; transfusion dependent thalassemia	Dove Medical Press Ltd	11787074		Article	Q2	722	6874	View
647(1)
No records
246	Ichwan S., Ningsih H.L., Aman R.A., Tandian D., Ashari S., Gunawan K., Nugroho S.W.	57192906639;57226696258;36848942500;57192891173;57195942105;57195935319;57460519700;	O6-methylguanine-dna methyltransferase (Mgmt) promoter methylation status of high-grade and low-grade gliomas	2021	Bali Medical Journal	10	2	644	647		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112380308&doi=10.15562%2fbmj.v10i2.2316&partnerID=40&md5=c8e8a17690a11b9cc2f1729ff7a40de8	Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia	Ichwan, S., Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Ningsih, H.L., Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Aman, R.A., Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Tandian, D., Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Ashari, S., Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Gunawan, K., Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Nugroho, S.W., Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia	Background: O6-methylguanine-DNA methyltransferase (MGMT) is a DNA-repair enzyme that correlates with tumor resistance mechanism to chemotherapy. Methylation of the MGMT promoter inhibits the cells from producing MGMT and is useful to predict chemotherapy’s effectiveness with alkylating agents. This study aims to evaluate the MGMT promoter methylation of low-grade and high-grade glioma in the Neurosurgery Department of Cipto Mangunkusumo National General Hospital. Methods: We evaluated MGMT promoter methylation status using methylation-specific polymerase chain reaction in low and high-grade glioma patients who underwent surgical resection in the Neurosurgery Department of Cipto Mangunkusomo Hospital Jakarta. The result then correlated with age, sex, Karnofsky Performance Scale (KPS), and glioma grading. Data were analyzed using SPSS version 20 for Windows. Results: MGMT promoter methylation was observed more often in patients diagnosed with age more than 40 years old than in patients less than 40 years old (85.7% vs. 50.0%), also more in men than women (77.7% vs. 50.0%). In patients with KPS more than 70 and KPS 70 or less, methylation of MGMT promoter was observed in 70.0% and 57.1%, respectively. Based on tumor grading, MGMT promoter methylation was observed more often in low-grade gliomas (WHO grade II) than high-grade gliomas (WHO grade II and IV) (85.7% vs. 50.0%). There was no significant relationship between gender, age, KPS, malignancy degree, and Overall Survival (OS) to the MGMT promoter methylation (p>0.05). Conclusion: MGMT promoter methylation was observed less in the higher grade of tumors (grade IV), lower KPS, younger age at the time of diagnosis, and female patients, although the differences were not statistically significant. MGMT promoter methylation was observed more often in gliomas with oligodendroglioma components. © 2021, Sanglah General Hospital. All rights reserved.	High-grade glioma; Low-grade glioma; Methylation; MGMT; Promoter		Sanglah General Hospital	20891180		Article	#N/A	#N/A	#N/A	View
65(2)
No records
710	Putrantyo I., Anilbhai N., Vanjani R., De Vega B.	57268843400;57268843500;57268728700;57222467939;	Tantalum as a novel biomaterial for bone implant: A literature review	2021	Journal of Biomimetics, Biomaterials and Biomedical Engineering	52		55	65	1	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115443615&doi=10.4028%2fwww.scientific.net%2fJBBBE.52.55&partnerID=40&md5=23de679861db060839b35e7a1cc36b26	Division of Surgery and Interventional Science, University College London, Royal Free Hospital Campus, London, United Kingdom; Faculty of Medicine Universitas Indonesia, Dr Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Cell & Tissue Bank, Dr Soetomo General Hospital, Surabaya, Indonesia	Putrantyo, I., Division of Surgery and Interventional Science, University College London, Royal Free Hospital Campus, London, United Kingdom, Faculty of Medicine Universitas Indonesia, Dr Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Anilbhai, N., Division of Surgery and Interventional Science, University College London, Royal Free Hospital Campus, London, United Kingdom; Vanjani, R., Division of Surgery and Interventional Science, University College London, Royal Free Hospital Campus, London, United Kingdom; De Vega, B., Division of Surgery and Interventional Science, University College London, Royal Free Hospital Campus, London, United Kingdom, Cell & Tissue Bank, Dr Soetomo General Hospital, Surabaya, Indonesia	Titanium (Ti) has been used in metallic implants since the 1950s due to various biocompatible and mechanical properties. However, due to its high Young’s modulus, it has been modified over the years in order to produce a better biomaterial. Tantalum (Ta) has recently emerged as a new potential biomaterial for bone and dental implants. It has been reported to have better corrosion resistance and osteo-regenerative properties as compared to Ti alloys which are most widely used in the bone-implant industry. Currently, Tantalum cannot be widely used yet due to its limited availability, high melting point, and high-cost production. This review paper discusses various manufacturing methods of Tantalum alloys, including conventional and additive manufacturing and also discusses their drawbacks and shortcomings. Recent research includes surface modification of various metals using Tantalum coatings in order to combine bulk material properties of different materials and the porous surface properties of Tantalum. Design modification also plays a crucial role in controlling bulk properties. The porous design does provide a lower density, wider surface area, and more immense specific strength. In addition to improved mechanical properties, a porous design could also escalate the material's biological and permeability properties. With current advancement in additive manufacturing technology, difficulties in processing Tantalum could be resolved. Therefore, Tantalum should be considered as a serious candidate material for future bone and dental implants. © 2021 Trans Tech Publications Ltd, Switzerland.	Bone implant; Porous metal; Porous structure; Surface coating; Tantalum	3D printers; Additives; Biocompatibility; Coatings; Corrosion resistant alloys; Dental alloys; Dental prostheses; Mechanical permeability; Metal implants; Porosity; Tantalum alloys; Titanium alloys; Bone implant; High costs; High melting point; Literature reviews; Metallic implants; Porous metal; Porous structures; Property; Surface coatings; Titanium (alloys); Corrosion resistance	Trans Tech Publications Ltd	22969837		Article	Q4	183	20493	View
748	Karina K., Ekaputri K., Biben J.A., Purwoko R.H., Sibuea T.P., Astuti S.L., Loho A.M., Limengka Y., Nelfidayani, Agustini S., Krisandi G., Maryam A., Rosadi I., Rosliana I., Sobariah S., Subroto W.R., Afini I., Widyastuti T., Zakiyah A., Ernanda D., Aini N., Jusryanti, Sulaeha A.D., Prestiani S.I., Donna I.M., Habibi, Mutiara M.S.	57212146678;57285088000;55947833300;57286031400;57286487800;57285797400;57223264641;37029815800;57286487900;57286488000;57225009844;57286260300;57204720098;57186671400;57203547382;57218940654;57211068324;57211074403;57226293808;57226273639;57226289464;57286944600;57226286645;57283770100;57284210300;57285797500;57284210400;	Evaluating the Safety of Intravenous Delivery of Autologous Activated Platelet-rich Plasma	2021	Journal of Health Sciences	11	2	61	65	2	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111033469&doi=10.17532%2fjhsci.2021.1276&partnerID=40&md5=b0a026ecaccc92d972564c5dfd1f4824	Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia; Pusat Kajian Stem Cell, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Indonesia	Karina, K., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia, Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia, Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia, Pusat Kajian Stem Cell, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia; Ekaputri, K., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Biben, J.A., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Purwoko, R.H., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Sibuea, T.P., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Astuti, S.L., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Loho, A.M., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Limengka, Y., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Nelfidayani, Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Agustini, S., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Krisandi, G., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Maryam, A., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Rosadi, I., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia, Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Indonesia; Rosliana, I., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Sobariah, S., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Subroto, W.R., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Afini, I., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Widyastuti, T., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Zakiyah, A., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Ernanda, D., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Aini, N., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Jusryanti, Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Sulaeha, A.D., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Prestiani, S.I., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Donna, I.M., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Habibi, Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Mutiara, M.S., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia	Introduction: Autologous platelet-rich plasma (PRP) has been a growing trend in the field of medicine due to its broad range of application and is considered safe from bloodborne diseases. Furthermore, various studies have tried to optimize the use of autologous PRP through various preparation protocols, including PRP activation. However, most of the studies available have not evaluated the safety for intravenous delivery of PRP, especially autologous activated PRP (aaPRP). Therefore, this study aimed to evaluate the safety of intravenous delivery of aaPRP. Methods: Blood was drawn from each patient and aaPRP was isolated through calcium activation and light irradiation. Each aaPRP was administered intravenously to all patients. Adverse events were documented and analyzed. Results: Six hundred eleven patients participated in this study with a total of 4244 aaPRP therapies. Quality control of autologous aaPRP showed no platelets present after both calcium activation and light irradiation. No adverse events such as allergic reaction, infection, and coagulation problems were observed on all patients over the course of the study. Conclusion: Our results showed that intravenous administration of autologous aaPRP is safe even in patients with various pathological conditions. © 2021. Karina Karina, et al.; licensee University of Sarajevo - Faculty of Health Studies. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.	Intravenous infusion; platelet-rich plasma; safety		University of Sarajevo - Faculty of Health Studies	22327576		Article	Q4	112	28273	View

Publikasi Scopus 926 artikel (Per 14 Maret 2022)